-+ 0.00%
-+ 0.00%
-+ 0.00%
BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals
Share
Listen to the news

https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/a991260828_bntxxcrcxenxfin.htm

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending